The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why should we assess variant allelic frequency in TP53-mutated AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Nicholas J. Short, MD Anderson Cancer Center, Houston, US. We asked, Why should we assess variant allelic frequency (VAF) in TP53-mutated AML?

Why should we assess variant allelic frequency in TP53-mutated AML?

Results from a retrospective study on patients with TP53-mutated AML, reported by Short, indicate that the impact of mutant TP53 VAF on clinical outcomes is treatment-dependent. Because of this, VAF should be assessed when considering therapy options.

Share: